JP Morgan Chase’s Nektar Therapeutics NKTR Stock Holding History

JP Morgan Chase’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-847	Closed	-$68K	–	6740
2022 Q1	$68K	Buy	847 +80	+10%	+$11.8K	﹤0.01%	5675
2021 Q4	$155K	Buy	+767	New	+$166K	﹤0.01%	5486
2021 Q2	–	Sell	-3,307	Closed	-$992K	–	6523
2021 Q1	$992K	Buy	+3,307	New	+$1.03M	﹤0.01%	4237
2020 Q1	–	Sell	-6,973	Closed	-$2.26M	–	5585
2019 Q4	$2.26M	Sell	6,973 -360	-5%	-$104K	﹤0.01%	3305
2019 Q3	$2M	Buy	7,333 +3,333	+83%	+$1.22M	﹤0.01%	3417
2019 Q2	$2.08M	Sell	4,000 -2,000	-33%	-$1M	﹤0.01%	3356
2019 Q1	$3.02M	Buy	6,000 +2,333	+64%	+$1.38M	﹤0.01%	3027
2018 Q4	$1.81M	Buy	3,667 +2,667	+267%	+$1.61M	﹤0.01%	3349
2018 Q3	$914K	Sell	1,000 -1,000	-50%	-$854K	﹤0.01%	3978
2018 Q2	$1.47M	Buy	+2,000	New	+$2.31M	﹤0.01%	3615
2018 Q1	–	Sell	-1,800	Closed	-$1.61M	–	5544
2017 Q4	$1.61M	Buy	+1,800	New	+$1.06M	﹤0.01%	3439
2017 Q3	–	Sell	-6,947	Closed	-$2.04M	–	5096
2017 Q2	$2.04M	Hold	6,947	–	–	﹤0.01%	3036
2017 Q1	$2.45M	Buy	+6,947	New	+$1.56M	﹤0.01%	2923

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's NKTR Position: Q2 2026 in Review

JP Morgan Chase reduced its Nektar Therapeutics (NKTR) stake by 91% in Q2 2026, selling an estimated $15.9M and leaving 22,138 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #4388.

JP Morgan Chase first reported a position in NKTR in Q2 2013 and has held it in 53 quarters since. The position peaked at $135M in Q1 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

JP Morgan Chase held 22,138 shares of Nektar Therapeutics worth $1.54M as of Q2 2026.
JP Morgan Chase sold 217,964 Nektar Therapeutics shares in Q2 2026, an estimated $15.9M.
Nektar Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4388 holding.
JP Morgan Chase first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 53 quarters since.
JP Morgan Chase's Nektar Therapeutics position peaked at $135M in Q1 2018.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.